期刊文献+

鼻咽癌患者放疗前氨磷汀两种给药方式不良反应观察 被引量:6

Observation of Adverse Effects of Amifostine Administered in Two Different Ways before Radiotherapy for Nasopharyngeal Carcinoma Patients
下载PDF
导出
摘要 目的观察比较鼻咽癌患者放疗前氨磷汀静脉和皮下注射两种给药方式不良反应的发生情况。方法将50例鼻咽癌放疗患者随机分成两组,两组均给予常规放疗,每周5次,每次2Gy。每周第1、第3、第5天放疗开始前60min使用氨磷汀400mg。对照组采用静脉注射给药,观察组采用皮下注射给药。观察比较两组患者不良反应。结果两组患者第1次使用氨磷汀后24h内发生呕吐情况比较,χ2=3.945,P<0.05,差异有统计学意义。两组患者用药后5min、15min血压分别与用药前5min比较,舒张压和收缩压均有所下降,观察组收缩压的下降幅度较对照组小,差异有统计学意义(P<0.05)。结论鼻咽癌放疗患者皮下注射氨磷汀能降低呕吐的发生率,避免低血压的发生,提高患者的舒适度及耐受性。
出处 《护理学报》 2009年第20期75-76,共2页 Journal of Nursing(China)
  • 相关文献

参考文献9

  • 1毛建芬.化疗前使用阿米福汀的观察与护理[J].护理与康复,2007,6(1):61-62. 被引量:7
  • 2谢昶.氨磷汀对细胞保护作用的研究现状[J].国外医药(抗生素分册),2001,22(2):84-90. 被引量:10
  • 3Kouvaris J R, Kouloulias V E, Vlahos L J. Amifostine:The First Selective-Target and Broad-Spectrum Radioprotector[J]. The Oncologist, 2007, 12(6):738-747.
  • 4Rades D, Fehlauer F, Bajrovic A, et al. Serious Adverse Effects of Amifostine during Radiotherapy in Head and Neck Cancer Patients[J].Radiother Oncol,2004,70(3):261-264.
  • 5Koukourakis M I, Kyrias G, Kakolyris S, et al. Subcutaneous Administration of Amifostine during Fractionated Radiotherapy:A Randomized Phase Ⅱ Study[ J ]. J Clin Oncol,2000,18 (11):2226-2233.
  • 6姜秋颖,路丹,信涛.氨磷汀的细胞保护作用对肿瘤化疗病人生活质量的改善[J].哈尔滨医科大学学报,2005,39(5):441-442. 被引量:5
  • 7Koukourakis M I, Simopoulos C, Minopoulos G,et al. Amifostine before Chemotherapy:Improved Tolerance Profile of the Subcutaneous over the Intravenous Route[ J ]. Clin Cancer Res,2003,9(9):3288-3293.
  • 8Bonner H S, Shaw L M. New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration with Intravenous Infusion[ J ]. J Clin Pharmacol,2002,42(2): 166-174.
  • 9黄和平,陈平,孙元美.循证护理在腹部皮下注射中的护理研究[J].护士进修杂志,2004,19(5):410-412. 被引量:65

二级参考文献19

  • 1龚丽萍,尹鸣.化学保护剂阿米福汀在晚期胃癌病人中的应用[J].现代肿瘤医学,2004,12(5):431-432. 被引量:11
  • 2陈均法,郑智茵,沈建平,胡致平,叶宝东.氨磷汀对淋巴瘤化疗病人重要脏器保护作用临床观察[J].中国现代应用药学,2005,22(5):424-426. 被引量:6
  • 3崔炎.护理学基础[M].北京:人民卫生出版社,2001.369.
  • 4Schuchter LM,Luginbuhl WE,Meropol NJ.The current status of toxicity protectants in cancer therapy[J].Semin Oncol,1992,19(6):742-751.
  • 5Illiano A,Barletta E,De Marino V,et al.New triplet che motherapy combination with carboplatin,paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer:a phase Ⅱ study[J].Anticancer Res,2000,20(5c):3999-4003.
  • 6Wadler S,Haynes H,Beitler JJ,et al.Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy.The New York Gynecologic Oncology Group[J].J Clin Oncol,1993,11(8):1517-1522.
  • 7周际昌.实用肿瘤内科学[M].北京,人民卫生出版社,2000.353-362.
  • 8孟家眉.神经内科临床新进展[M].北京∶北京人民出版社,1995.120.
  • 9Fulvio Marzatico,Camillo Porta,Mauro Moroni,Laura Bertorelli,Elena Borasio,Nicoletta Finotti,Orietta Pansarasa,Laura Castagna. In vitro antioxidant properties of amifostine (WR-2721, Ethyol)[J] 2000,Cancer Chemotherapy and Pharmacology(2):172~176
  • 10Abdul-Kader Souid,Robert C. Fahey,Ronald L. Dubowy,Gerald L. Newton,Mark L. Bernstein. WR-2721 (amifostine) infusion in patients with Ewing’s sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study[J] 1999,Cancer Chemotherapy and Pharmacology(6):498~504

共引文献83

同被引文献39

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部